Atherosclerosis is a ubiquitous disorder that begins in childhood. An autopsy study of 2,876 adolescents and young adults (ages 15-34) who died of external causes found fatty streaks in the aorta of 100% of subjects, and in the right coronary artery in half the subjects. 1 The number and extent of lesions increased with age. The incidence of fibrous plaque, a marker of a healed lesion in males was *3% in subjects [15] [16] [17] [18] [19] , increasing to *20% in the 30-34-year-old group, suggesting that the lesions evolve over time. Macroscopic calcium in the lesion, however, was rare in these young subjects, \1% in subjects ranging from 15 to 29 years of age, increasing slightly to *1% in the 30-34-year-old age group.
The pervasive presence of atheroma suggests that some of these lesions will progress to cause clinical disease. Cerebral transient ischemic attacks and stroke are major clinical manifestations of atherosclerosis in the carotid artery. 2 An estimated 6.6 million men and women[20 years of age in the US have a history of stroke. 1 Approximately, 795,000 people experience a new or recurrent (ischemic or hemorrhagic) stroke each year. Approximately, 610,000 of these are first events and 185,000 are recurrent stroke events. In 2011, stroke caused 140,000 deaths in the US. The most common therapy for patients with severe carotid stenosis, stroke, or recurrent transient ischemic attacks is carotid endarterectomy.
Approximately, 100,000 endarterectomy procedures were performed in the US in 2010. 2 Although carotid stenting has gained popularity (accounting for *13% of carotid artery revascularization in 2008), a randomized trial of outcomes in 2,502 patients after carotid stenting or endarterectomy suggested that in patients over the age of 70 3 , there was a lower rate of recurrent stroke in endarterectomy patients.
Characteristics of carotid plaques at risk of causing a clinical event include: 4, 5 Thin fibrous cap (\65 lm), large lipid core, evidence of intraplaque hemorrhage, and active plaque inflammation. Additional characteristics of unstable plaque are eccentric distribution of the lesion (due to arterial remodeling) and an irregular surface. 4 An intact thick fibrous cap (seen on CT, MR or US) has a low risk of rupture, a thin cap is associated with a mild risk of rupture and a fissured fibrous cap is associated with a high risk of rupture (often due to shear stress). 6 Another common cause of plaque rupture is a sudden increase in plaque volume and pressure due to intraplaque hemorrhage, as is commonly seen in coronary lesions. 7, 8 A large number of macrophages and a necrotic core increase the likelihood of intraplaque hemorrhage due to the release of enzymes within the atheroma (e.g., matrix metalloproteinases 9 ) that weaken the fragile vasavasorum.
At the time a fatty streak develops, injured endothelium and lipid laden macrophages produce chemoattractant molecules. 10 The quantity of integrin produced increases as inflammation and lesion size progress. 11 Progression of inflammation in atheroma causes participation of the immune system, attracting cytolytic T cells into the lesion. 12 These T cells promote cytolysis and apoptosis of smooth muscle cells, endothelial cells, and macrophages. Plaque mineralization, once considered a 'tombstone' of atheroma, is now appreciated as a marker with a bimodal distribution. Initial calcium deposition is scattered in necrotic areas and in the cap. This microcalcification (calcium aggregates \60 lm) occurs in response to proinflammatory stimuli. 13 This type of calcification, often visible on fluorine-18 ( 18 F-fluoride) imaging and high resolution micro CT in laboratory studies, can increase shear stress on the cap, increasing the likelihood of rupture of a thin fibrous cap plaque.
14 If inflammation abates, vascular smooth muscle cells may undergo osteogenic transdifferentiation, resulting in the formation of homogeneous sheet-like macrocalcification, stabilizing the plaque. 13 Lesions with macrocalcification are readily visible on clinical CT.
One approach to imaging late stage carotid atheroma is described in this issue of the Journal. Golestani et al 15 incubated a novel a v b 3 fluorine-18 labeled RGD peptide with carotid endarterectomy specimens harvested from 16 patients with symptomatic or stenotic (70%-99%) atherosclerotic lesions. The a v b 3 fluorine-18 labeled RGD peptide (RGD-K5) has nanomolar affinity for integrin expressed on inflamed arterial tissue. Carotid endarterectomy specimens from 3 additional patients were incubated with the tracer and a 550-fold excess of unlabeled RGD-K5 as a blocking study to demonstrate the specificity of uptake. Following incubation, the specimens were washed and imaged with microPET. Localization of the peptide in the 16 endarterectomy specimens was heterogeneous, with foci of greater uptake correlating with the endothelial cell marker CD31 and a v b 3 expression on immune histology. Although the investigators were able to show a correlation between histology and tracer localization, the limited number of random comparisons they performed likely underestimated the histologic significance of the imaging results. The blocking studies demonstrated a 6-fold decrease in RGD-k5 uptake, confirming the specificity of the tracer. The heterogeneity of RGD-K5 uptake in the lesions may also reflect the interval between the patient's last clinical event and the time of endarterectomy. Redgrave et al demonstrated a 20% decrease in carotid lesion inflammation in endarterectomy specimens obtained *50 days after a clinical event, and a further 20% decline by *100 days after the clinical event. 5 In addition to the integrin described by Golestani, other molecular tracers have been described to image atheroma. The lesion is permeable to low-density lipoprotein bound cholesterol, which can be detected with radiolabeled autologous LDL. 16 As the endothelial permeability is repaired, residual LDL-cholesterol in the subendothelium results in inflammation. The inflammation causes the endothelial cells to produce chemoattractant peptides. 17, 18 The mononuclear cells attracted to the site may effectively 'treat' the lesion by phagocytosis of the residual LDL-cholesterol, often leaving a small fibrous scar. If there is another episode of damage to the intimal cells, the process is repeated. This repetitive process can occur multiple times, frequently without complete resolution, leaving an area of inflammation and necrosis in the vessel wall. Persistent subendothelial inflammation causes vascular remodeling Localizes in ruptured and high-risk lesions and formation of a fibrous cap, separating the flowing blood from the thrombogenic, inflamed subendothelial atheroma. The agents suggested to image atheroma are part of the inflammasome, 19 a series of markers that are increased in chronic inflammation. At each phase in the evolution of atheroma, one or more molecular markers have been described to image the lesion. Table 1 is a partial list of agents proposed for this purpose.
Identifying patients with atheroma at high risk of a clinical event at a time when organ function is intact, is a high priority for preventive care. In the case of atheroma, an imaging procedure with high sensitivity for lesion detection and high predictive value for a clinical event within 2 years, is required to be clinically useful. The study by Golestani is one more step along the path to develop such a procedure.
